Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

Código QR

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

Monica Iorfida, Manuelita Mazza, Elisabetta Munzone Division of Medical Senology, European Institute of Oncology, IRCCS, Milano 20141, ItalyCorrespondence: Elisabetta MunzoneDivision of Medical Senology, European Institute of Oncology, IRCCS, via Ripamonti 435, Milano 20141, ItalyTel +39 02 57489970...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iorfida M, Mazza M, Munzone E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	metastatic breast cancer cyclin-dependent kinases 4 and 6 fulvestrant clinical trials resistance mechanisms palbociclib ribociclib abemaciclib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e694915222e5428886b3e22c2c99c156
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Erin R. Scheidemann, et al.
Publicado: (2021)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa D, et al.
Publicado: (2017)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li Y, et al.
Publicado: (2020)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
por: Betheney R. Pennycook, et al.
Publicado: (2021)

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells
por: Qiong Cheng, et al.
Publicado: (2021)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Yannan Zhao, et al.
Publicado: (2018)

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
por: Editorial Board
Publicado: (2021)

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer
por: Cenzhu Wang, et al.
Publicado: (2021)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
por: Irina V. Kolyadina, et al.
Publicado: (2021)

Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study
por: Chao Li, et al.
Publicado: (2021)

Metastatic Breast Cancer to the Urinary Bladder in the Caribbean
por: Saara Mohammed, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021)

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: R.K. Ismail, et al.
Publicado: (2021)

In Vitro Investigations of miR-33a Expression in Estrogen Receptor-Targeting Therapies in Breast Cancer Cells
por: Pelin Ozfiliz-Kilbas, et al.
Publicado: (2021)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
por: Naiba Nabieva, et al.
Publicado: (2021)

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
por: Timothée Olivier, et al.
Publicado: (2022)

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
por: Editorial Board
Publicado: (2021)

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
por: Jiaojiao Suo, et al.
Publicado: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Functional characterization of CDK10 and cyclin M truncated variants causing severe developmental disorders
por: Thomas Robert, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
por: Mateusz Malik, et al.
Publicado: (2021)

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
por: A. Migeotte, et al.
Publicado: (2021)

SHORT-TERM RESULTS OF SIMULTANEOUS SURGERIES AT METASTATIC COLORECTAL CANCER
por: A. S. Zagaynov, et al.
Publicado: (2017)

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
por: Irina V. Kolyadina, et al.
Publicado: (2020)

The <italic toggle="yes">Toxoplasma</italic> Centrocone Houses Cell Cycle Regulatory Factors
por: Anatoli Naumov, et al.
Publicado: (2017)

IP<sub>7</sub>-SPX Domain Interaction Controls Fungal Virulence by Stabilizing Phosphate Signaling Machinery
por: Desmarini Desmarini, et al.
Publicado: (2020)

Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
por: Rashid N, et al.
Publicado: (2016)

Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis
por: Dara Brena, et al.
Publicado: (2022)

Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer
por: Zhuang J, et al.
Publicado: (2021)

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
por: Xuan Cheng, et al.
Publicado: (2021)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Lillian M. Smyth, et al.
Publicado: (2021)

Nanotechnology-enhanced immunotherapy for metastatic cancer
por: Peisen Zhang, et al.
Publicado: (2021)

Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer
por: Olivia Ruhen, et al.
Publicado: (2021)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
por: Abeer J. Al-Qasem, et al.
Publicado: (2021)